Initial Albumin-Bilirubin Grade as a Prognostic Indicator of Pancreatic Cancer with Liver Metastasis
Received Date : 26 Nov 2021
Accepted Date : 05 Jan 2023
Available Online : 24 Jan 2023
Doi: 10.37047/jos.2021-87242 - Article's Language: EN
J Oncol Sci.
This is an open access article under the CC BY-NC-ND license
Objective: Pancreatic cancer (PCa) is the fourth leading cause of cancer-related deaths. Thus, there is a need for prognostic indicators that can aid in disease classification and subsequent selection of appropriate treatment options. Albumin-bilirubin (ALBI) grade, which is calculated using a logarithmic formula, is indicative of liver function. The present study evaluated the prognostic performance of the initial ALBI grade for metastatic PCa in patients receiving first-line chemotherapy. Material and Methods: In this retrospective study, the medical records of 114 patients with de novo liver metastatic PCa and unresectable liver metastasis were evaluated. The ALBI grade was calculated using the formula (log10 bilirubin × 0.66) + (albumin × -0.085), and based on the grade, patients were divided into 3 groups, namely, ALBI Grade 1, ≤-2.60; ALBI Grade 2, between −2.60 and -1.39; and ALBI Grade 3, ≥-1.39. Results: Median progression-free survival (PFS) was 13 months [95% confidence interval (CI), 7.3-18.6]. The estimated PFS was 16 months for ALBI Grade 1 (95% CI, 13.0-20.4), 8 months for ALBI Grade 2 (95% CI, 7.5-9.9), and 5 months for ALBI Grade 3 (95% CI, 4.3-5.6). Median overall survival (OS) was 11 months (95% CI, 9.0-12.9). The estimated OS was 18 months for ALBI Grade 1 (95% CI, 14.4-21.5), 9 months for ALBI Grade 2 (95% CI, 7.8-10.1), and 6 months for ALBI Grade 3 (95% CI, 4.1-7.8; p<0.001). Conclusion: The initial ALBI grade demonstrated outstanding performance as an independent prognostic factor in PCa patients with liver metastasis.
  1. Siegel RL, Miller KD, Jemal A.Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. [Crossref]  [PubMed] 
  2. Chan KKW, Guo H, Cheng S, et al.Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreaticcancer: A population-based propensity score-weighted analysis. Cancer Med. 2020;9(1):160-169. [Crossref]  [PubMed]  [PMC] 
  3. Qian Y, Gong Y, Fan Z, et al.Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J HematolOncol. 2020;13(1):130. [Crossref]  [PubMed]  [PMC] 
  4. Kleeff J, Korc M, Apte M, et al.Pancreatic cancer. Nat Rev Dis Primers. Apr 2016;2:16022. [Crossref]  [PubMed] 
  5. Johnson PJ, Berhane S, KagebayashiC, et al. Assessment of liver function in patients with hepatocellular carcinoma: a newevidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-558. [Crossref]  [PubMed]  [PMC] 
  6. Wang Z, Fan Q, Wang M, Wang E, LiH, Liu L. Comparison between Child-Pugh Score and albumin-bilirubin grade in patientstreated with the combination therapy of transarterial chemoembolization and sorafenib forhepatocellular carcinoma. Ann Transl Med. 2020;8(8):537. [Crossref]  [PubMed]  [PMC] 
  7. Yukimoto A, Hirooka M, Hiraoka A,et al. Using ALBI score at the start of sorafenib treatment to predict regorafenib treatmentcandidates in patients with hepatocellular carcinoma. Jpn J Clin Oncol. 2019;49(1):42-47. [Crossref]  [PubMed] 
  8. Kanda M, Tanaka C, Kobayashi D, etal. Preoperative albumin-bilirubin grade predicts recurrences after radical gastrectomy inpatients with pT2-4 gastric cancer. World J Surg. 2018;42(3):773-781. [Crossref]  [PubMed] 
  9. Abdel-Rahman O. Prognostic valueof baseline ALBI score among patients with colorectal liver metastases: a pooled analysis oftwo randomized trials. Clin Colorectal Cancer. 2019;18(1):e61-e68. [Crossref]  [PubMed] 
  10. Zhang J, Xu Q, Zhang H, Zhang Y,Yang Y, Luo H, et al. High preoperative albumin-bilirubin score predicts poor survival inpatients with newly diagnosed high-grade gliomas. Transl Oncol. 2021;14(4):101038. [Crossref]  [PubMed]  [PMC] 
  11. Yagyu T, Saito H, Sakamoto T, etal. Preoperative albumin-bilirubin grade as a useful prognostic indicator in patients withpancreatic cancer. Anticancer Res. 2019;39(3):1441-1446. [Crossref]  [PubMed] 
  12. Wen J, Chen J, Liu D, Xu X, FanM, Zhang Z. The eighth edition of the American joint committee on cancer distant metastasesstage classification for metastatic pancreatic neuroendocrine tumors might be feasible formetastatic pancreatic ductal adenocarcinomas. Neuroendocrinology. 2020;110(5): 364-376. [Crossref]  [PubMed] 
  13. Lala V, Zubair M, Minter DA. Liver Function Tests. 2022. In: StatPearls.Treasure Island (FL): StatPearls Publishing; 2022.
  14. Tufoni M, Baldassarre M,Zaccherini G, Antognoli A, Caraceni P. Hemodynamic and systemic effects of albumin inpatients with advanced liver disease. Curr Hepatol Rep. 2020;19(3):147-158. [Crossref]  [PubMed]  [PMC] 
  15. Hinds TD Jr, Creeden JF, GordonDM, et al. Bilirubin nanoparticles reduce diet-induced hepatic steatosis, improve fatutilization, and increase plasma β-hydroxybutyrate. Front Pharmacol. Dec 2020;11:594574. [Crossref]  [PubMed]  [PMC] 
  16. Fargo MV, Grogan SP, Saguil A. Evaluation of jaundice in adults. Am FamPhysician. 2017;95(3):164-168. [PubMed] 
  17. Hiraoka A, Michitaka K, Kumada T,et al. Validation and potential of albumin-bilirubin grade and prognostication in anationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a moredetailed evaluation of hepatic function. Liver Cancer. 2017;6(4):325-336. [Crossref]  [PubMed]  [PMC] 
  18. Grivennikov SI, Greten FR, KarinM. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899. [Crossref]  [PubMed]  [PMC] 
  19. Singh N, Baby D, Rajguru JP,Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med.2019;18(3):121-126. [Crossref]  [PubMed]  [PMC] 
  20. Zhu C, Wang X, Chen S, et al.Efficacy of the preoperative albumin-bilirubin grade for predicting survival and outcomes ofpostoperative chemotherapy for advanced gastric cancer. Cancer Manag Res. Nov2020;12:11921-11932. [Crossref]  [PubMed]  [PMC] 
  21. Küçükarda A, Gökyer A, Gökmenİ, et al. Prognostic effect of albumin-bilirubin grade on survival in advance gastriccancer patients with de-novo liver metastasis. Journal of Oncological Sciences.2020;6(3):133-140. [Crossref] 
  22. Zhang TN, Yin RH, Wang LW. Theprognostic and predictive value of the albumin-bilirubin score in advanced pancreaticcancer. Medicine (Baltimore). 2020;99(28):e20654. [Crossref]  [PubMed]  [PMC] 
  23. Imamura T, Okamura Y, Sugiura T,et al. Clinical significance of preoperative albumin-bilirubin grade in pancreatic cancer.Ann Surg Oncol. 2021;28(11):6223-6235. [Crossref]  [PubMed] 
  24. Sakin A, Sahin S, Sakin A, et al. Assessment of pretreatmentalbumin-bilirubin grade in pancreatic cancer patients with liver metastasis. J BUON.2020;25(4):1941-1946. [PubMed] 
  25. Feng L, Gu S, Wang P, et al.Pretreatment values of bilirubin and albumin are not prognostic predictors in patients withadvanced pancreatic cancer. Cancer Med. 2018;7(12):5943-5951. [Crossref]  [PubMed]  [PMC]